Skip to Content

Dongfeng Motor Group Resumes Trading as Subsidiary Voyah Prepares Hong Kong Listing

Illustrates strategic corporate restructuring in the automotive sector, encompassing parallel moves...
Key Metrics

11.26

Heat Index
  • Impact Level
    Medium
  • Scope Level
    National
  • Last Update
    2025-08-25
Key Impacts
Positive Impacts (5)
Voyah Automobile
Dongfeng Motor Group Co. Ltd.
Chinese Automobile Manufacturers
Hong Kong Exchanges & Clearing Ltd. (HKEX)
Hang Seng China Enterprises Index (HSCEI)
Total impacts: 5 | Positive: 5 | Negative: 0
Event Overview

Illustrates strategic corporate restructuring in the automotive sector, encompassing parallel moves for subsidiary public listings and parent company privatization. Highlights market mechanisms involved in share trading suspensions, resumptions, and product relaunches connected to financial maneuvers. Exemplifies the intersection of capital market activity and corporate governance, reflecting broader trends of asset reorganization, listing strategies, and their regulatory implications in major exchanges.

Collect Records
Dongfeng Motor Group Resumes Trading; Subsidiary Voyah to List on HKEX
2025-08-25 09:09

On the morning of August 25, Dongfeng Motor Group Company Limited announced on the Hong Kong Stock Exchange that trading in its shares would resume at 9:00 a.m. All related structured products would also resume trading at the same time. The company previously announced that its subsidiary, Voyah Automobile, will be listed on the Hong Kong Stock Exchange by way of introduction, and Dongfeng Motor Group will complete privatization and delisting in parallel. According to the announcement, the transaction involves a payment method combining Voyah Automobile equity and cash, with a total acquisition price of HK$10.85 per share, including a cash consideration of HK$6.68 per share and an equity consideration of HK$4.17 per share.

Total records: 1
FDA Grants Approval to Innovent Biologics' IBI363 for Global Phase III NSCLC Clinical Trial
The advancement of novel immune therapies underscores intensifying competition in the oncology...